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tRNAProkaryotic aminoacylated-transfer RNAs often need to be efﬁciently segregated between transla-
tion and other cellular biosynthetic pathways. Many clinically relevant bacteria, including Strepto-
coccus pneumoniae, Staphylococcus aureus, Enterococcus faecalis and Pseudomonas aeruginosa direct
some aminoacylated-tRNA species into peptidoglycan biosynthesis and/or membrane phospholipid
modiﬁcation. Subsequent indirect peptidoglycan cross-linkage or change in membrane permeabil-
ity is often a prerequisite for high-level antibiotic resistance. In Streptomycetes, aminoacylated-
tRNA species are used for antibiotic synthesis as well as antibiotic resistance. The direction of coding
aminoacylated-tRNA molecules away from translation and into antibiotic resistance and synthesis
pathways are discussed in this review.
 2013 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Protein synthesis by ribosomes utilizes aminoacyl-tRNAs to
translate the codons of mRNA into the corresponding polypeptide
sequence. Within the cell, each aminoacyl-tRNA species is pro-
duced by a two-stage reaction that is catalyzed speciﬁcally by
one of twenty aminoacyl-tRNA synthetase enzymes (aaRSs). In
the ﬁrst stage of the reaction, an amino acid is activated with aden-
osine triphosphate (ATP) to form an aminoacyl-adenylate with
concurrent release of inorganic pyrophosphate (PPi). In the second
stage of the reaction, the activated amino acid moiety is trans-
ferred either to the 20 or the 30 hydroxyl of adenine-76 at the 30
end of the bound tRNA substrate with the subsequent formation
of an aminoacyl–ester bond [1,2]. Following this process, the
aminoacylated-tRNA product is released and sequestered by elon-
gation factor Tu (EF–Tu) for delivery to the ribosome and use in
protein synthesis (Fig. 1) [3,4]. Aminoacylated tRNA substrates
are also required for cellular processes outside of translation
including both peptidoglycan and antibiotic biosynthesis pathways
in prokaryotes (Fig. 2). The processes that sequester aminoacyl-
tRNAs away from translation so that they can, instead, be used in
other speciﬁc biosynthetic pathways will be discussed in this
review.2. Direction of aminoacyl-tRNA into peptidoglycan biosynthesis
Peptidoglycan is a key component of the bacterial cell wall
responsible for providing protection against osmotic stress and
turgor pressure [5]. It forms a thicker layer in Gram-positive bacte-
ria, many of which also heavily use the structure for anchoring of
important virulence factors, when compared to Gram-negative
bacteria [6]. The carbohydrate backbone of peptidoglycan consists
of an alternating chain of N-acetylglucosamine (GlucNAc) and N-
acetylmuramic acid (MurNAc) residues with a pentapeptide side
chain attached to the lactyl ether appendage of the latter compo-
nent. A single GlucNAc–MurNAc pentapeptide subunit in combina-
tion with undecaprenyl-pyrophosphate is the building block for
peptidoglycan formation and is commonly referred to as Lipid II.
Pentapeptide side chains are comprised of alternating D- and L-
amino acids with an overall common structure of L-Ala-c-D-Glu-
X-D-Ala-D-Ala. Gram-negative bacteria typically have meso-diami-
nopimelic acid at position X whereas in Gram-positive bacteria this
is replaced most frequently by L-Lys [7]. An additional level of
peptidoglycan structure is obtained by cross-linking between the
pentapeptide side chains of adjacent strands. The rigidity of the ﬁ-
nal murein structure is dictated by the degree of cross-linking.
Typically Gram-negative bacteria, such as Escherichia coli, have a
low level of pentapeptide cross-linking (25–50%) in comparison
to Gram-positive bacteria (70–90%). In addition to this, cross-links
can either be direct, involving linkage of the amino acid at position
Fig. 1. Formation of an amino acid-tRNA pair by an aminoacyl-tRNA synthetase (aaRS). An amino acid (blue) is activated by an aaRS to form an aminoacyl-adenylate. This
process requires adenosine triphosphate (ATP) and results in the release of pyrophosphate (PPi). Following tRNA binding to the aaRS, the activated amino acid is transferred to
the 30 end of the tRNA molecule forming aminoacyl-tRNA with concurrent release of adenosine monophosphate (AMP). The aminoacyl-tRNA product is released from the
aaRS and is either subject to binding by elongation factor Tu (EF–Tu) for delivery to the ribosome or hijacking by other factors for diversion into biosynthetic pathways outside
of translation. Figure reproduced with permission from [2].
Fig. 2. Cellular biosynthetic pathways that utilize aminoacyl-tRNAs as substrates.
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position of another, or indirect which ﬁrst requires the formation
of a connecting amino acid bridge. Indirect cross-linking is more
common in bacteria that have L-Lys at position X and the structure
of the required intervening amino acid bridge can vary between
different genera and species [7,8]. The amino acids required for
bridge formation are typically derived from appropriately aminoa-
cylated-tRNA donor molecules. Utilization of these donor tRNA
molecules in peptidoglycan biosynthesis and how this relates to
antibiotic resistance, are discussed below.
2.1. MurM and MurN in Streptococcus pneumoniae
The peptidoglycan layer of S. pneumoniae is unusual in that it
contains a combination of both linear and branched muropeptides
within the structure. Branched muropeptides carry either an L-Ala-
L-Ala or an L-Ser-L-Ala dipeptide that is attached to the third L-Lys
of the pentapeptide side chain of Lipid II [9] (Fig. 3). Formation of
this dipeptide substrate for indirect peptidoglycan cross-linking re-
quires the activities of the MurM and MurN tRNA-dependent ami-
noacyl-ligases. MurM and MurN are encoded within an operon by
the ﬁbA and ﬁbB (factors important in b-lactam resistance) genes,
respectively. In addition, MurMN activity is functionally conserved
across all strains of pneumococcus [10,11]. Selective inactivation of
these two genes has shown that the protein products act within a
speciﬁc order. MurM is responsible for the addition of either L-Alaor L-Ser as the ﬁrst amino acid of the cross-link and then MurN
invariably adds L-Ala as the second amino acid [12]. In both cases,
appropriately aminoacylated-tRNA species serve as the amino acid
donors for the reaction [13]. Provision of adequate substrates for
MurMN is currently thought to be achieved solely by the activities
of alanyl- and seryl-tRNA synthetases within this bacterium. No
MurMN-speciﬁc tRNA isoacceptors have been identiﬁed to date
that would explain how a balance between direction of these
aminoacylated-tRNA species into the protein and peptidoglycan
biosynthesis pathways is either established or maintained.
In 1990, prior to the identiﬁcation of the ﬁbAB operon, a link
was established between levels of indirect cross-linking in the
pneumococcal cell wall and penicillin resistance. At this time, it
was observed that a penicillin-resistant isolate from South Africa
had a highly branched peptidoglycan that could be co-transferred
with penicillin resistance to susceptible pneumococci [14,15].
Since then, many highly penicillin-resistant strains of pneumococ-
cus have also been shown to have an increased level of branched
muropeptides within their cell wall in comparison to penicillin-
sensitive isolates. Further investigation by insertion duplication
mutagenesis targeting the ﬁbAB operon showed that inactivation
of MurMN had no signiﬁcant effect on cell viability. Notably, inter-
ruption of the ﬁbAB operon in S. pneumoniae strain Pen6 caused a
marked reduction in penicillin resistance from 6 to 0.032 lg ml1.
This effect was also seen in other penicillin-resistant strains of
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Fig. 3. The role of MurM and MurN in cell wall branching using Lipid II as substrate. Lipid II is comprised of N-acetylated disaccharide units of glucosamine (yellow hexagon
labeled G) and muramic acid (pink hexagon labeled M). The pentapeptide side chain is enzymatically attached to the muramic acid residues. Lipid II itself is anchored via
bactoprenyl pyrophosphate (pink zig-zag line) to the plasma membrane. MurM is an aminoacyl ligase responsible for the addition of either L-Ser or L-Ala to the cell-wall
precursor L-Lys residue. MurN is responsible for the invariable addition of L-Ala as the second amino acid of the cross-link. Reproduced with permission from [9].
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determinants of b-lactam resistance within this bacterium [10].
Further elucidation of the role of MurMN in b-lactam resistance
has been complicated by the ﬁnding that transformation with a
MurM allele from a penicillin-resistant strain enriches branched
muropeptides but does not increase penicillin-resistance. This sug-
gests that, whilst MurM is necessary for high-level penicillin resis-
tance, it is not sufﬁcient in the absence of low afﬁnity forms of the
penicillin binding proteins. It has also been demonstrated that
inactivation of murMN results in increased susceptibility to cell ly-
sis during exposure to low concentrations of other antibiotics that
target peptidoglycan biosynthesis including fosfomycin, vancomy-
cin, D-cycloserine and nisin. This is predictive of stress response
mediated re-direction of aminoacylated-tRNA species into pepti-
doglycan biosynthesis via the MurM and MurN proteins [12,16,17].
2.2. FemXAB in Staphylococcus aureus
Indirect cross-linking within the peptidoglycan of S. aureus re-
quires modiﬁcation of the Lipid II intermediate with a pentaglycine
bridge, which is subsequently used as a platform for anchoring
many virulence factors within this bacterium [5,18]. Pentaglycine
bridge formation is catalyzed in a three-step process by the
tRNA-dependent aminoacyl ligases FemX (FhmB), FemA and FemB.
The genes encoding FemXAB are transcribed from an operon and
the protein products act in a speciﬁc order. FemX is responsible
for addition of the ﬁrst Gly residue of the bridge [19,20]. Following
this, FemA sequentially adds two more Gly residues prior to penta-
glycine bridge completion by FemB. All three of these proteins
require Gly-tRNAGly as the amino acid donor and adequate provi-
sion of this substrate within the cell is achieved by glycyl-tRNAsynthetase [21]. This is, in part, aided by the fact that three out
of the ﬁve tRNAGly isoacceptors encoded in the S. aureus genome
have sequence identity elements consistent with weak binding to
EF–Tu [22]. These speciﬁc sequence elements include replacement
of the strong EF–Tu binding pairs G49–U65 and G51–C63 [23–25]
with A49–U65 and A51–U63, respectively, in the TWC loop. In addi-
tion the three non-proteinogenic tRNAGly isoacceptors also exhibit
replacement of GG at positions 18 and 19 with either UU or CU
[22]. This allows S. aureus to maintain adequate provision of Gly-
tRNAGly for two essential processes: translation and cell wall mod-
iﬁcation by the FemXAB proteins, even though it only has one
glycyl-tRNA synthetase encoded in its genome [22].
Determination of the X-ray crystal structure of FemA indicated
that the protein likely has only one binding site for Gly-tRNAGly
[26]. This initially indicated that an additional aminoacyl-tRNA
binding event would be required for transfer of the second Gly res-
idue by this protein. Further studies resulted in the detection of
protein–protein interactions between two monomers of FemA,
twomonomers of FemB and also between FemA and FemB directly.
No such interactions were found for FemX [27]. This suggests that
FemX carries out its function as a monomer whereas FemA and
FemB carry out their functions as homodimers. Dimerization of
two FemA monomers and then, in a separate event, two FemB
monomers, would allow for transfer of one Gly residue to Lipid II
by each of the proteins in the dimer without the need for an addi-
tional tRNA binding event [27].
In contrast to S. pneumoniae, indirect peptidoglycan cross-link-
ing in S. aureus is essential for cell viability as determined by femX
inactivation studies. Furthermore, selective femA or femB inactiva-
tion was determined to be lethal without the acquisition of com-
plementary mutations due to a combination of phenotypic
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tent, reduction in cell wall turnover, disruption to cell septum for-
mation, retarded separation of cells and loss of methicillin
resistance with concurrent increase in sensitivity to b-lactam anti-
biotics [28–30]. These detrimental effects make sequestration of
Gly-tRNAGly away from protein synthesis and into peptidoglycan
synthesis essential in this bacterium.
2.3. Lif and Epr in Staphylococcus simulans and Staphylococcus capitis
Both S. simulans and S. capitis produce glycyl–glycine endopep-
tidases that speciﬁcally target and cleave the pentaglycine bridge
that is formed during indirect cross-linking of staphylococcal pep-
tidoglycan. Possession of such endopeptidases confers a competi-
tive advantage on these particular bacteria during niche
colonization in the presence of other staphylococcal species. In or-
der to protect itself from its own endopeptidase (lysostaphin), S.
simulans speciﬁcally produces lysostaphin immunity factor, other-
wise known as Lif [31]. Similarly, S. capitis produces endopeptidase
resistance factor, or Epr, to provide protection against its endopep-
tidase Ale-1 [32]. Lif and Epr have been shown to have up to 41%
identity to FemAB and, therefore, it is no surprise that they require
aminoacylated-tRNA species for their function. Lif and Epr have a
high speciﬁcity for incorporation of Ser instead of Gly at the third
and ﬁfth position of the typical staphylococcal pentaglycine bridge.
The resulting peptidoglycan structure, which has an interpeptide
bridge comprised of alternating Ser and Gly, is protected from
hydrolysis by the glycyl–glycine endopeptidases as they are unable
to break the peptide bonds between these two amino acids [33].
Currently, it is not known how Lif and Epr hijack Ser-tRNASer away
from protein synthesis, however, neither of these proteins are able
to extend the monoglycine bridge found in femAB deletion strains.
Therefore it is clear that they depend on FemA and FemB in some
way for activity [33]. L-Ser has also been detected in the peptido-
glycan cross-links of other staphylococci including S. epidermidis
[34].
2.4. FemX in Weissella viridescens
In W. viridescens, indirect peptidoglycan cross-linking involves
the formation of an L-Ala-L-Ser or an L-Ala-L-Ser-L-Ala peptide
bridge. Within this bacterium, the Ala-tRNA-dependent enzyme,
FemX, achieves initiation of peptide bridge formation by transfer
of the ﬁrst L-Ala residue to the epsilon amino group of L-Lys found
at the third position of the pentapeptide side chain. The enzymes
involved in the subsequent transfer of the second position Ser
and third position Ala residues have not yet been formally identi-
ﬁed [35]. In contrast to the substrate speciﬁcity of many of the
other Fem enzymes, W. viridescens FemX exclusively utilizes the
cytoplasmic peptidoglycan precursor, UDP-MurNAc pentapeptide,
rather than membrane bound Lipid II [36]. Kinetic characterization
of W. viridescens FemX has indicated that its catalytic mechanism
can be divided into four highly ordered and sequential stages. In
the ﬁrst two stages, the enzyme binds to UDP-MurNAc and then
to Ala-tRNAAla. In the third stage, L-Ala is transferred from the
bound tRNA donor molecule to the accepting L-Lys at the third po-
sition of the pentapeptide side chain. Finally the reaction is com-
pleted by release of the tRNA donor and the UDP-MurNAc
hexapeptide product. Asp-108 has been identiﬁed as an essential
residue within FemX since mutation to Asn is directly correlated
with a 230-fold reduction in the catalytic efﬁciency of the enzyme
[37]. Recent crystallization of FemX in complex with a peptidyl–
tRNA conjugate has identiﬁed Lys-305 and Phe-304 as additional
critical residues for optimal catalytic activity of the enzyme.
Replacement of Lys-305 with Ala, Met or Arg decreases the turn-
over number of the enzyme by 1.3  104-, 1.9  102- and9.9  102-fold, respectively. The critical nature of this highly con-
served Fem-ligase family residue is likely due to the amine stabiliz-
ing effect it has during the development of a negative charge on the
carbonyl group of L-Ala upon nucleophilic attack of the Ala-tRNAAla
ester bond by the amine group of L-lysine in the pentapeptide side
chain. In contrast, replacement of Phe-304 with Ala or Leu de-
creases the turnover number of the enzyme by 16- and 29-fold,
respectively. This is due to the critical nature of this residue in
establishing correct stacking interactions between the enzyme
and its tRNA substrate [38].
The X-ray crystal structure of FemX shows that it has two do-
mains, each with a distinct role. The ﬁrst domain of the protein
is involved in the binding of UDP-MurNAc, whereas the presence
of a positively charged channel across domain II indicates a poten-
tial role in the accommodation and binding of the negatively
charged backbone of the Ala-tRNAAla substrate [39]. Following on
from this discovery, the interaction of FemX with its second sub-
strate has been characterized by the introduction of speciﬁc mod-
iﬁcations within both the tRNA and the amino acid moiety. These
studies indicated that FemX has a preference for L-Ala addition to
UDP-MurNAc pentapeptide because it reacts much more unfavor-
ably with both L-Ser and the acceptor arm of tRNAGly. More specif-
ically, in vitro activity assays show that FemX turns over Ser-
tRNASer and Gly-tRNAGly 17- and 38-fold less efﬁciently than Ala-
tRNAAla, respectively. In the latter case, this can be explained by
site-directed mutagenesis studies indicating the importance of
the penultimate base pair of tRNAAla, G2-C71, as an essential iden-
tity element for FemX. This is typically replaced by C2-G71 in
tRNAGly species [40]. Speciﬁc FemX residues involved in tRNA
binding have been identiﬁed by crystallization of the enzyme with
a peptidyl–RNA conjugate and include Ile-208, which forms a
hydrophobic interaction with the CCA end of the aminoacyl-tRNA
substrate. In addition to this, Arg-205, Ser-259 and His-206 form
a hydrogen-bonding network that stabilizes the phosphates of
the C75 and A76 nucleotides located at the 30 terminus of the tRNA
substrate [38]. W. viridescens FemX has been shown to speciﬁcally
transfer Ala from tRNA that is aminoacylated on the 20 hydroxyl of
adenine-76 of the tRNA molecule [35,41]. This may account for
successful substrate competition with the A site of the ribosome
which transfers amino acids from the 30 hydroxyl of the tRNA using
the 20 hydroxyl as a catalyst for peptide bond formation [42].
2.5. BppA1 and BppA2 in Enterococcus faecalis
The peptidoglycan of E. faecalis comprises a series of indirect
cross-links that result from the production of an L-Ala-L-Ala dipep-
tide bridge. The dipeptide bridge is attached to the epsilon amino
group of the third position L-Lys of the pentapeptide side chain
in a process that requires alanyl-tRNA synthetase, Ala-tRNAAla
and the two Fem ligases BppA1 and BppA2. BppA1 is responsible
for transfer of the ﬁrst Ala of the dipeptide to its cytoplasmic pre-
cursor, UDP-MurNAc pentapeptide. BppA2 is subsequently respon-
sible for transfer of the second Ala residue. BppA1 and BppA2 are
orthologues of the S. pneumoniae Fem proteins sharing 39% identity
to MurM and 38% identity to MurN at the amino acid level, respec-
tively. Deletion of BppA2 results in a peptidoglycan structure com-
prised of a mono-Ala bridge and simultaneous reduction in the
intrinsic b-lactam resistance level of this bacterium. Resistance of
E. faecalis to third generation cephalosporins results from produc-
tion of a speciﬁc low afﬁnity penicillin binding protein, PBP5, by
nearly all members of the species. Optimal activity of PBP5 re-
quires peptidoglycan precursor substrates to carry the completed
di-Ala bridge [43]. Therefore, successful diversion of Ala-tRNAAla
away from protein synthesis and into this alternative pathway
has direct effects on b-lactam resistance. The mechanism by which
Ala-tRNAAla partitioning is achieved in E. faecalis to ensure
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glycan biosynthesis is currently unknown.
2.6. FemX and VanK in Streptomyces coelicolor
S. coelicolor peptidoglycan is indirectly cross-linked by virtue of
a mono-Gly branch that is attached to meso-diaminopimelic acid
at the third position of the cytoplasmic UDP-MurNAc pentapeptide
side chain precursor. Mono-Gly branch formation is achieved by
one of the Gly-tRNA-dependent aminoacyl ligases FemX or VanK.
FemX and VanK are not active at the same time and control of their
gene expression depends upon vancomycin levels in the immedi-
ate environment of the bacterium. In the absence of vancomycin,
FemX, which recognizes UDP-MurNAc pentapeptide terminating
in D-Ala-D-Ala, is active and responsible for the addition of mono-
Gly to the third position of the side chain. Conversely, in the pres-
ence of this antibiotic, expression of the vancomycin gene cluster,
VanSRJKHAX, is switched on by the two component regulatory sys-
tem VanRS [44]. Expression from this gene cluster results in Van-
HAX mediated termination of the pentapeptide side chain of
UDP-MurNAc in D-Ala-D-Lactate (Lac) instead of D-Ala-D-Ala. Since
vancomycin is unable to bind pentapeptide that terminates in D-
Ala-D-Lac, this minor change in the peptidoglycan precursor is en-
ough to confer vancomycin resistance on S. coelicolor. FemX is un-
able to recognize UDP-MurNAc pentapeptide terminating in D-Ala-
D-Lac and so cannot branch the precursor in the presence of vanco-
mycin. Therefore, to maintain cell viability in the presence of this
antibiotic, FemX activity is substituted for by VanK activity [45].
The factors involved in diversion of Gly-tRNAGly away from protein
synthesis and into peptidoglycan biosynthesis in S. coelicolor are
currently unknown.
3. Direction of aminoacylated-tRNA into antibiotic biosynthesis
and resistance pathways
In addition to having essential roles in protein synthesis and
Gram-positive peptidoglycan cross-linking, aminoacyl-tRNAs are
also used in pathways directly implicated in antibiotic biosynthesis
and resistance. These reactions involve different amino acid-tRNA
pairs and a variety of acceptor molecules as discussed below.
3.1. MprF mediated antibiotic resistance
MprF proteins are broadly deﬁned as virulence factors that con-
trol the permeability of the cell wall to cationic antimicrobials by
catalyzing the aminoacylation of inner membrane lipids (reviewed
in [46]. Aminoacylation of membrane lipids adjusts the net nega-
tive charge of the membrane bilayer in a manner that is dependent
on the aminoacyl-tRNA substrate [47]. The most well character-
ised MprF proteins are the aminoacyl-phosphatidylglycerol syn-
thases (aa-PGSs). The aa-PGSs are integral membrane proteins
found in the cytoplasmic membrane of both Gram-positive and
Gram-negative bacteria. These enzymes are directly responsible
for the transfer of amino acids from aminoacyl-tRNA donors to
the polar head group of the common membrane lipid, phosphati-
dylglycerol [48]. In each case, aa-PGSs have an N-terminal mem-
brane-spanning domain that varies in length and is thought to
be involved in ﬂipping the aminoacylated-phospholipid across
the membrane. At the C-terminus, there is a separate hydrophilic
domain that catalyzes the aminoacylation process [49]. Some
forms of aa-PGSs, including LysX in Mycobacterium tuberculosis,
also have a bound tRNA synthetase enzyme that is dedicated to
providing the MprF part of the protein with its charged tRNA sub-
strate [50].
In some bacteria, including Clostridium perfringens, S. aureus
and M. tuberculosis, Lys-tRNALys is used both for translation andas a substrate for the aminoacylation of membrane lipids
[48,50–52]. Within these organisms, aa-PGSs transfer the amino
acid from Lys-tRNALys to phosphatidylglycerol. The overall effect
of this process is an increase in the net positive charge of the
cytoplasmic membrane. This subsequently lowers permeability
to cationic molecules including defensins, aminoglycosides, b-
lactams and glycopeptides. Recently, aa-PGSs that are able to
transfer amino acids other than Lys to phosphatidylglycerol have
been discovered. C. perfringens and Pseudomonas aeruginosa both
have Ala-PGSs which are able to aminoacylate phosphatidylglyc-
erol with Ala and thus neutralize the overall charge of the mem-
brane [48,53]. This modiﬁcation has been shown to enhance the
resistance of P. aeruginosa to a multitude of negatively charged
b-lactam antibiotics such as oxacillin and methicillin as well as
providing protection against acidic or osmotically stressful
growth conditions. E. faecium has been shown to have an aa-PG
with triple speciﬁcity for Ala, Arg and Lys [54]. This is indicative
of the fact that these aa-PG enzymes confer antibiotic resistance
by a combination of two mechanisms: lowering the net negative
charge of the membrane and altering its general biophysical
properties including ﬂuidity and permeability. The latter of these
two underexplored mechanisms could result in signiﬁcant
changes in the membrane proteome and a shift in the expression
of virulence phenotypes.
The process of directing appropriately aminoacylated-tRNA do-
nor molecules into membrane lipid modiﬁcation and away from
protein synthesis is not fully understood. Since MprF and EF–Tu
have been demonstrated to have comparable afﬁnities for Lys-
tRNALys under physiological conditions (Fig. 4, [53]), it is possible
that different MprF proteins sample different aminoacylated-tRNA
substrates under different environmental conditions [48]. This may
be directly related to the availability of these donor molecules
within the intracellular aminoacyl-tRNA pool at the time, which
is likely to change based upon the growth conditions of the bacte-
rium. Alternatively, MprF expression could be down regulated un-
der such conditions to reduce the detrimental effect of competition
with the translation machinery for the same aminoacylated-tRNA
donor molecules.
3.2. VlmA mediated valanimycin synthesis in Streptomyces
viridifaciens
Within the genome of S. viridifaciens there is a 14-gene cluster
encoding for the biosynthesis of the naturally occurring azoxy-con-
taining antibiotic, valanimycin. Valanimycin is derived from L-Val
to L-Ser via isobutylamine and isobutylhydroxylamine intermedi-
ates. Encoded within the valanimycin biosynthesis gene cluster,
there is a dedicated class II seryl-tRNA synthetase, VlmA. VlmA is
only 39% homologous to the other housekeeping seryl-tRNA syn-
thetase found within this actinomycete. This can be explained by
the different substrate speciﬁcity of VlmA, which is responsible
for the transfer of L-Ser from Ser-tRNASer to the hydroxyl group
of isobutylhydroxylamine. The product of the VlmA catalyzed reac-
tion is O-(L-seryl)-isobutylhydroxylamine, which is subsequently
able to rearrange spontaneously to form N-(L-seryl)-isobutylhydr-
oxylamine [55,56]. The reaction catalysed by VlmL is essential for
efﬁcient production of valanimycin as demonstrated by gene dis-
ruption studies. Phenotypic effects seen in a vlmA mutant suggest
that the Ser-tRNASer produced by the S. viridifaciens housekeeping
seryl-tRNA synthetase can be directed into valanimycin production
but very inefﬁciently. Potential explanations for this have included
the possible compartmentalization of the valanimycin pathway
within this bacterium or inability of VlmA to access the full set
of tRNASer isoacceptors in the cell [57]. The mechanisms for direct-
ing tRNASer into the valanimycin pathway rather than translation
have not been fully characterized.
Fig. 4. Partitioning of Lys-tRNALys between protein synthesis and membrane lipid modiﬁcation by MprF proteins. Lys-speciﬁc MprF (LysPGS) and Elongation factor Tu (EF–Tu)
show comparable afﬁnities for Lys-tRNALys potentially allowing this aminoacylated tRNA species to enter two different biosynthetic pathways simultaneously. Reproduced
with permission from [95].
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coeruleorubidus
Genome mining within S. coeruleorubidus has resulted in the
identiﬁcation of a biosynthetic gene cluster that allows this bacte-
rium to synthesize members of the anti-pseudomonal pacidamycin
family of antibiotics [58]. Pacidamycins are broadly deﬁned as a
group of uridyl tetra- or pentapeptide antibiotics that target the
MraY translocase in the prokaryotic peptidoglycan biosynthesis
pathway [59]. The common scaffold for all pacidamycins is based
upon a central Nb-methyl 2S,3S-diaminoburytic acid (DABA) moi-
ety. The DABA moiety typically has an N-terminal amino acid
(Ala/m-Tyr2) and a bicyclic heterocycle or dipeptide (Ala/Gly1-m-
Tyr2). In addition, there is a C-terminal ureido dipeptide (Ala4-
Phe/Trp/m-Tyr5) and a carboxy-linkage to a 30-deoxy-40,50-enami-
nouridine [60]. Production of the 50 aminouridyl-tetrapeptide
pacidamycin framework requires a total of nine non-ribosomal
peptide synthetases [61]. Speciﬁcally, PacN generates the ureido
dipeptide moiety of the scaffold and PacD subsequently ligates this
to the a-amino region of DABA. DABA is then further modiﬁed at
the carboxyl group by PacI-catalyzed addition of an amide-linked
modiﬁed uridine moiety. Addition of the N-terminal Ala/Gly1 has
been shown to require PacB, a structural homologue of W. virides-
cens FemX (see Section 2.4 of this review). PacB has functional
similarity to the Fem ligases due to its role in the transfer of
L-Ala from aminoacyl-tRNA donors to the m-Tyr2 residue of the
growing PacH-anchored antibiotic scaffold. No pacidamycin-dedi-
cated aminoacyl-tRNA synthetases or tRNAs have been found
within the gene cluster encoding the components for synthesis of
this class of antibiotic. This suggests that PacB must sequester ami-
noacyl-tRNA donors in direct competition with the protein synthe-
sis pathway [62]. The mechanism by which this is achieved and
controlled is currently unknown.
3.4. Cyclodipeptide synthesis
Cyclodipeptides form a large class of natural secondary metab-
olites that belong to the diketopiperazine (DKP) family [63]. Many
of these secondary metabolites are potentially clinically relevant
exhibiting a broad range of biological activities [64,65] including
those that are antibacterial [66–68], antifungal [69,70], antiviral
[71], immunosuppressive [72], antitumor [73–76] or anti-inﬂam-
matory [77] in nature. Initial characterization of cyclodipeptide
synthesis pathways resulted in the hypothesis that non-ribosomal
peptide synthetases are essential to the process due to their role incatalysis of DKP scaffold formation [63]. In 2002, a non-ribosomal
peptide synthetase-independent DKP biosynthesis pathway was
discovered in Streptomyces noursei [78]. Characterization of this
albonoursin synthesis pathway identiﬁed a unique tRNA-depen-
dent cyclodipeptide synthase, AlbC. AlbC is catalytically
responsible for the synthesis of the albonoursin precursor cy-
clo(L-Phe-L-Leu) from Phe- and Leu-tRNA substrates. This precursor
is then converted to albonoursin by a cyclic dipeptide oxidase that
is responsible for two sequential a,b-dehydrogenations [63,78].
Since the discovery of AlbC, two other prokaryotic cyclodipeptide
synthase-requiring pathways have been characterized. Synthesis
of the cyclo(L-Leu-L-Leu) precursor for the iron chelator, pulcherri-
min, in Bacillus subtilis requires the Leu-tRNA-dependent cyclodi-
peptide synthase, YvmC. After its synthesis, cyclo(L-Leu-L-Leu) is
then converted to the iron-binding unit, pulcherriminic acid, by
CypX-catalyzed diketopiperazine ring oxidation [63,79]. In M.
tuberculosis, the cyclo(L-Tyr-L-Tyr) precursor for the potential cell
viability factor mycocyclosin is produced by the Tyr-tRNA-depen-
dent cyclodipeptide synthase Rv2275. Following its synthesis, the
cyclo(L-Tyr-L-Tyr) precursor is subjected to C–C aryl coupling by
CYP121 to form the ﬁnal mycocyclosin product [63,80,81]. Follow-
ing elucidation of the pathways employed by these three cyclodi-
peptide synthases, it has been determined that they form a
unique family of enzymes detected across at least 50 different
bacterial genomes. The enzyme family is most well represented
across Actinobacteria, Proteobacteria and Firmicutes but they have
also been found in Bacteroidetes, Chlamydiae, Cyanobacteriae and
ﬁve eukaryotic genomes. Despite this fairly broad evolutionary
distribution, cyclodipeptide synthases show very little to no signif-
icant structural and functional similarity to the non-ribosomal
peptide synthetases or Fem ligases. Sequence alignment of nine
members of this family has resulted in identiﬁcation of conserva-
tion at only seven residues (Gly-35, Ser-37, Gly-79, Tyr-128,
Tyr-178, Glu-182 and Tyr-202) and no apparent essential consen-
sus sequence was found (reviewed in [82]). Therefore, it is
currently unclear how the cyclodipeptide synthases hijack amino-
acylated-tRNA species from primary metabolism (Fig. 5).
4. Diverting aminoacyl-tRNAs away from translation
In addition to their primary role in translation, aminoacyl-
tRNAs are also critical substrates for other cellular processes
including peptidoglycan biosynthesis, membrane lipid modiﬁca-
tion, protein tagging for N-end rule degradation (reviewed in
[83]), synthesis of other tRNAs to compensate for an absent
Fig. 5. Hijacking of aminoacylated-tRNA donor molecules by cyclodipeptide synthases for use in biosynthesis of the natural secondary metabolites, cyclodipeptides.
Aminoacylated-tRNA donor molecules are generated by aminoacyl-tRNA synthetases (aaRS, shown in red). Typically the aminoacylated-tRNA product of the aaRS catalyzed
reaction is bound by elongation factor Tu (EF–Tu) and delivered to the ribosome (shown in green) for use in protein synthesis. Cyclodipeptide synthases (blue) must hijack
certain aminoacylated tRNA species and divert them into the cyclodipeptide biosynthesis pathway. Putative steps in the pathway are shown in italics. Reproduced and
modiﬁed with permission from [82].
J. Shepherd, M. Ibba / FEBS Letters 587 (2013) 2895–2904 2901aminoacyl-tRNA synthetase (reviewed in [84]), tetrapyrrole syn-
thesis (reviewed in [84]), antibiotic biosynthesis and antibiotic
resistance pathways. With recent advances in post-genomic tech-
niques ensuring the frequent discovery of novel aminoacyl-tRNA-
dependent pathways, there is renewed interest in both the pro-
teins that are involved in hijacking these substrates from primary
metabolism and in the associated mechanisms that ensure this
does not become detrimental to the cell.
The mechanism for ensuring adequate diversion of aminoacy-
lated-tRNA donor molecules into peptidoglycan biosynthesis,
thereby surpassing direct competition from the translation
machinery, depends upon the bacterium and, in some cases, is still
not fully understood. In S. aureus, three of the ﬁve encoded tRNAGly
isoacceptors escape protein synthesis and are, instead, directed
into pentaglycine peptidoglycan cross-bridge formations by virtue
of them containing sequence speciﬁc identity elements that are
associated with weak binding to EF–Tu. In S. epidermidis, both Ser
and Gly are found within the penta-amino acid peptidoglycan
cross-bridge, and at least two of the identiﬁed tRNAGly isoacceptors
(named IA and IB) participate in peptidoglycan synthesis but not in
translation [46,85]. Both of these tRNA molecules differ from oth-
ers in that their dihydrouridine (D) loops contain an unusually
low number of modiﬁed uridine nucelotides as well as lacking
guanine at positions 18 and 19. In addition to this, the D-loop of
IB has two opposing uridine residues that prevent the normal for-
mation of the ﬁrst base pair of this stem structure. In both species,
the typical GTWC sequence found in many tRNAs is replaced by
GUGC and there is an additional base pairing event in the antico-
don loop, between C32 and G38, which may distort this region
enough to prevent binding to the ribosome, thus accounting for
efﬁcient escape into peptidoglycan biosynthesis [86,87]. Incontrast, no single species of tRNASer or mutations within this mol-
ecule have been identiﬁed that would allow it to act as an exclusive
Ser donor for peptidoglycan biosynthesis. In fact, it has been dem-
onstrated that Ser is integrated into the penta-amino acid bridge of
this bacterium in a random manner and approximately 20% of the
cross-links within S. epidermidis strain Texas 26 consist solely of
Gly [88]. This suggests that Ser integration could be regulated by
growth conditions or environmental factors that would make it
beneﬁcial for Ser-tRNASer to be hijacked away from protein synthe-
sis. For example, it would be advantageous for S. epidermidis to in-
crease levels of Ser in its peptidoglycan cross-bridges during
colonization of a niche inhabited by other staphylococcal species
that are able to produce and secrete glycyl–glycine endopeptidases
[31,32]. This is plausible when it is taken into consideration that
the two well characterized glycl–glycine endopeptidase secreting
staphylococcal species, S. simulans and S. capitis (reviewed in Sec-
tion 2.3), have both been isolated from human skin, which is also
the common niche of S. epidermidis [89].
Since indirect peptidoglycan cross-linking has only been di-
rectly correlated with cell viability in members of the genus Staph-
ylococcus, it is of no surprise that the Fem ligases within this
bacterium are provided with designated non-proteinogenic
tRNAGly isoacceptors to perform this task. No such designated tRNA
isoacceptors have been identiﬁed in S. pneumoniae or W. virides-
cens, the two other well characterized bacterial systems that exhi-
bit Fem ligase mediated indirect peptidoglycan cross-linking.
MurMN from S. pneumoniae require Ser-tRNASer and Ala-tRNAAla
as amino acid donors whereas W. viridescens FemX requires only
the latter species. In both cases, attempts to characterize the sub-
strate speciﬁcities ofW. viridescens FemX and S. pneumoniaeMurM
have indicated that they only accept the amino acid moiety from
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This contrasts with the described speciﬁcity of the ribosome, which
utilizes tRNA species that are aminoacylated on the 30 hydroxyl
group of adenine-76 [42]. Spontaneous trans-esteriﬁcation of the
amino acid between the 30 and the 20 hydroxyl group of the termi-
nal adenine of any tRNA molecule ensures that these species exist
in a 2:1 ratio at equilibrium [91]. Therefore this differential speci-
ﬁcity of MurM and FemX in comparison to the ribosome may be
one mechanism that is exploited by the cell to ensure adequate
provision of aminoacyl-tRNA species for translation and peptido-
glycan biosynthesis.
In addition to mechanisms based on dedicated tRNAs, some
non-ribosomal biosynthetic pathways depend on dedicated ami-
noacyl-tRNA synthetases. Some MprF proteins, most notably LysX
in M. tuberculosis, have a bound tRNA synthetase enzyme that is
dedicated to providing the MprF part of the protein with its
charged tRNA substrate [50]. The valanimycin antibiotic biosyn-
thesis pathway in S. viridifaciens has a dedicated seryl-tRNA syn-
thetase that is responsible for production of the Ser-tRNASer
intermediate [55]. Within these systems, presence of a dedicated
synthetase could directly address the problem of substrate compe-
tition with the translation machinery by ensuring the required
aminoacyl-tRNA species are directly transferred to the proteins in-
volved in these pathways without being subjected to sampling by
EF–Tu. The pacidamycin and characterized cyclodipeptide biosyn-
thesis pathways do not encode dedicated aminoacyl-tRNA synthe-
tase enzymes and are likely to hijack aminoacylated-tRNA donors
directly from primary metabolism [58,82]. Therefore, the balance
between translation and these pathways may shift in favour of
the later during stages in the growth cycle when production of
these compounds is advantageous to the bacterium. How this is
achieved is currently unknown and further studies are required
to fully understand the interactions of these proteins with their
tRNA substrates[62,82].5. Future perspectives
Aminoacyl-tRNA species are the prevalent amino acid donors in
the cell due to their critical role as substrates for ribosomal protein
biosynthesis. It has become increasingly clear that aminoacyl-
tRNAs are also utilized in an ever-growing number of other non-
ribosomal biosynthetic pathways particularly in bacteria, although
some pathways also exist in eukaryotes [92]. To date over half of
the 20 canonical aminoacyl-tRNAs required to translate the genetic
code have been shown to have one or more alternative functions in
bacteria, and it is likely that many more will be found to have roles
in other pathways in all domains of life. As discussed here, there is
a clear link between many of the non-ribosomal aminoacyl-tRNA
dependent activities and antibiotic resistance or production, and
other stress responses. As a result of this, further characterization
of these pathways may enable development of methodologies for
increasing the yield of natural antibiotic biosynthesis. More impor-
tantly, research into these pathways will also provide the potential
for identiﬁcation of new drug targets, which could restore the po-
tency of antibiotics already used in the clinical setting. Of particu-
lar interest here may be the discovery of ‘‘missing links’’ in some of
these non-ribosomal aminoacyl-tRNA dependent pathways, which
might be expected to fall into two broad categories. Firstly, it is
possible that non-canonical aminoacylation events may provide
new and useful substrates to diversify non-ribosomal biosynthetic
pathways just as they do for protein synthesis [93]. Secondly, the
partitioning of substrates away from protein synthesis may require
the presence of dedicated complexes either between know factors
[94], which in some cases may be fused [50], or the presence of as
yet uncharacterized factors that can sequester substrates fornon-ribosomal pathways. Overall, it seems clear that our current
understanding of the role of aminoacyl-tRNAs outside of protein
synthesis will continue to expand and add to our broader under-
standing of how translation and other cellular pathways are linked.
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